Aclaris Therapeutics has dosed the first subject in the Phase IIa clinical trial of ATI-2138 to treat moderate to severe ...

Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Atopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

异位性皮肤炎不仅会伤害患者的皮肤，也可能影响生活质量和日常活动。新加坡中央医院将在9月13日（星期五）举办“异位性皮肤炎——不止是皮肤表层问题”（Atopic Dermatitis – More than skin deep?）线上英语讲座。

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

在社交媒体光鲜滤镜的背后，许多饱受特应性皮炎困扰的患者往往会通过“精修”的图片来“隐藏”皮肤问题，而他们在日常生活中遭受的挑战也常被公众忽视和误解。作为皮肤科的“一号疾病”，特应性皮炎（Atopic Dermatitis，简称“AD”）具有遗传性和家族史的特征，属于免疫介导炎症性疾病（简称IMID），我国现有高达3000万人深受其扰，主要表现为湿疹样皮疹和难以忍受的剧烈瘙痒。